The DOI matches its Crossref record, with a small difference in title or year; 209 of the 209 references it cites were found in a registry or an index.
Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association
Abstract
The process of atherosclerosis may begin in youth and continue for decades, leading to both nonfatal and fatal cardiovascular events, including myocardial infarction, stroke, and sudden death. With primordial and primary prevention, cardiovascular disease is largely preventable. Clinical trial evidence has shown convincingly that pharmacological treatment of risk factors can prevent events. The data are less definitive but also highly suggestive that appropriate public policy and lifestyle interventions aimed at eliminating tobacco use, limiting salt consumption, encouraging physical exercise, and improving diet can prevent events. There has been concern about whether efforts aimed at primordial and primary prevention provide value (ie, whether such interventions are worth what we pay for them). Although questions about the value of therapeutics for acute disease may be addressed by cost-effectiveness analysis, the long time frames involved in evaluating preventive interventions make cost-effectiveness analysis difficult and necessarily flawed. Nonetheless, cost-effectiveness analyses reviewed in this policy statement largely suggest that public policy, community efforts, and pharmacological intervention are all likely to be cost-effective and often cost saving compared with common benchmarks. The high direct medical care and indirect costs of cardiovascular disease—approaching $450 billion a year in 2010 and projected to rise to over $1 trillion a year by 2030—make this a critical medical and societal issue. Prevention of cardiovascular disease will also provide great value in developing a healthier, more productive society.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regular assessments of lipids, glycemia, and kidney function (eg, eGFR) are recommended with increasing frequency for higher CKM stages, as the risk for progressive metabolic and kidney disease increases along the CKM spectrum.13,18–21”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [13]
In the citing paper
“Experiencing weight stigma may be independently associated with worse clinical outcomes.13”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [13]
In the citing paper
“SDOH, the nonmedical risk factors impacting disease risk and health outcomes, play a critical role in CKM health across the life course.11–14”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [13]
In the citing paper
“Furthermore, weight loss maintenance is often challenging.13”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [13]
In the citing paper
“Among patients who have undergone MBS and have regained a significant amount of weight (≥25% or more of total lost weight), GLP-1–based therapies can be useful in promoting weight loss and management of comorbidities.9–13”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [13]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
The Health Belief Model: a decade later.
Janz, N. K., & Becker, M. H. (1984) · Health Education Quarterly · doi:10.1177/109019818401100101 · Cited by 8,437
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Physical Activity in the United States Measured by Accelerometer
TROIANO, R. P., BERRIGAN, D., DODD, K. W., MÂSSE, L. C., TILERT, T., & MCDOWELL, M. (2008) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31815a51b3 · Cited by 7,638
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Research works printed but not linked: 14
- Prevention for a Healthier America: Investments in Disease Prevention Yield Significant Savings, Stronger Communities. Washington, DC: Trust for America's Health; 2008.
- Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services Public Health Service; May 2008.
- Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: Institute of Medicine; 2009.
- Recommended Community Strategies and Measurements to Prevent Obesity. Atlanta, GA: Centers for Disease Control and Prevention; 2009.
- Commission on Social Determinants of Health: Final Report. Geneva, Switzerland: World Health Organization; September 2, 2009.
- Committee on Secondhand Smoke Exposure and Acute Coronary Events, Institute of Medicine. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: Institute of Medicine; 2009.
- Behavioral Risk Surveillance System. Atlanta, GA: Centers for Disease Control and Prevention; 2009.
- 10.1093/ajcn/82.1.174 · doi:10.1093/ajcn/82.1.174
- Proceedings of the Task Force Meeting: Worksite Reviews. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
- Lambrew JM, Podesta JD. Promoting Prevention and Preempting Costs: A New Wellness Trust for the United States. Washington, DC: Center for American Progress; 2006.
- Fruit and Vegetable Consumption Among Adults: United States, 2005. Atlanta, GA: Centers for Disease Control and Prevention; 2007;56:213–217.
- Smoking Cessation Policy: The Economic Benefit. Washington, DC: American Lung Association; September 14, 2010.
- National Center for Health Statistics: National Health Interview Survey. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Health Statistics; 2006.
- Alchian A. The meaning of utility measurement. Am Econ Rev. 1953;43:26–50.
Cited by
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Self-citationHeart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Self-citation
Metadata
- Authors
- Weintraub, W. S., Daniels, S. R., Burke, L. E., Franklin, B. A., Goff, D. C., Hayman, L. L., Lloyd-Jones, D., Pandey, D. K., Sanchez, E. J., Schram, A. P., & Whitsel, L. P.
- ORCID
- Venue
- Circulation
- Published
- 2011-08-23
- Volume
- 124
- Issue
- 8
- Pages
- 967-990
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2009642737
- Cited by
- 541
- References
- 209
- Citations by year
- 2026: 23 · 2025: 21 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 36 · 2020: 29 · 2019: 29 · 2018: 41 · 2017: 27 · 2016: 33 · 2015: 54 · 2014: 41 · 2013: 45 · 2012: 46
- FWCI
- 42.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- cardiovascular disease prevention, primordial prevention, primary prevention, cost-effectiveness, atherosclerosis, public health policy, lifestyle intervention, tobacco use, salt intake, physical activity, cardiovascular disease costs
- MeSH terms
- American Heart Association, Cardiovascular Diseases, Humans, Risk Factors, United States, Evidence-Based Medicine, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association. https://app.cochat.ai/papers/10.1161/cir.0b013e3182285a81
- The paper
- Weintraub, W. S., Daniels, S. R., Burke, L. E., Franklin, B. A., Goff, D. C., Hayman, L. L., Lloyd-Jones, D., Pandey, D. K., Sanchez, E. J., Schram, A. P., & Whitsel, L. P. (2011). Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association. Circulation. https://doi.org/10.1161/cir.0b013e3182285a81
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.